Free shipping on all orders over $ 500

MSC2504877

Cat. No. M28495

All AbMole products are for research use only, cannot be used for human consumption.

MSC2504877 Structure
Synonym:

M2912

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.


Quality Control & Documentation
Biological Activity

MSC2504877 (M2912) is a potent and orally active tankyrase inhibitor with IC50s of 0.0007, 0.0008, 0.54 µM for TNKS, TNKS2, PARP1, respectively. MSC2504877 increases the expression of AXIN2 and TNKS protein levels and decreases β-catenin levels. MSC2504877 shows anti-tumor activity.

Chemical Information
Molecular Weight 282.34
Formula C17H18N2O2
CAS Number 1460286-21-8
Form Solid
Solubility (25°C) DMSO 125 mg/mL (ultrasonic)
Storage Powder -20°C
References

[1] Malini Menon, et al. Sci Rep. A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors

Related PARP Products
2-Methylquinazolin-4-ol

2-Methylquinazolin-4-ol is a potent competitive poly(ADP-ribose) synthetase inhibitor, with a Ki of 1.1 μM. 2-Methylquinazolin-4-ol mammalian aspartate transcarbamylase (ATCase) inhibitor, with IC50 of 0.20 mM.

DPQ 

DPQ is a potent PARP-1 inhibitor.

OUL232 

OUL232 is a potent inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and PARP15.

AZ3391 

AZ3391 is a potent inhibitor of PARP.

PARP1-IN-5 

PARP1-IN-5 is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM).

  Catalog
Abmole Inhibitor Catalog




Keywords: MSC2504877, M2912 supplier, PARP, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.